Jie Jin

2.6k total citations
64 papers, 913 citations indexed

About

Jie Jin is a scholar working on Oncology, Hematology and Molecular Biology. According to data from OpenAlex, Jie Jin has authored 64 papers receiving a total of 913 indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Oncology, 23 papers in Hematology and 21 papers in Molecular Biology. Recurrent topics in Jie Jin's work include Multiple Myeloma Research and Treatments (12 papers), Lymphoma Diagnosis and Treatment (11 papers) and CAR-T cell therapy research (9 papers). Jie Jin is often cited by papers focused on Multiple Myeloma Research and Treatments (12 papers), Lymphoma Diagnosis and Treatment (11 papers) and CAR-T cell therapy research (9 papers). Jie Jin collaborates with scholars based in China, United States and South Korea. Jie Jin's co-authors include Junmin Li, Liuping Zhang, Genbao Shao, Aihua Gong, Jianda Hu, Hongyan Tong, Jianrong Sang, Meijuan Huang, Ziqiang Yu and Xiaojun Xu and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Jie Jin

55 papers receiving 901 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jie Jin China 16 381 341 290 142 113 64 913
Tarek H. Mouhieddine United States 18 447 1.2× 457 1.3× 230 0.8× 111 0.8× 93 0.8× 61 1.2k
Mary Kwok United States 12 484 1.3× 340 1.0× 590 2.0× 78 0.5× 99 0.9× 32 975
Hussein A. Abbas United States 18 524 1.4× 279 0.8× 392 1.4× 44 0.3× 141 1.2× 79 1.1k
Agata Filip Poland 17 319 0.8× 160 0.5× 73 0.3× 90 0.6× 140 1.2× 67 751
Sara Redaelli Italy 19 463 1.2× 260 0.8× 505 1.7× 120 0.8× 58 0.5× 41 1.2k
Christina Schmidt Germany 14 460 1.2× 234 0.7× 131 0.5× 35 0.2× 134 1.2× 27 1.0k
Frances Bennett United Kingdom 8 285 0.7× 354 1.0× 179 0.6× 42 0.3× 388 3.4× 13 934
Toby N. Trahair Australia 26 708 1.9× 384 1.1× 251 0.9× 93 0.7× 113 1.0× 87 1.8k
R Schlossman United States 11 781 2.0× 629 1.8× 801 2.8× 126 0.9× 174 1.5× 19 1.4k
Cristina Ferrari Italy 18 448 1.2× 265 0.8× 180 0.6× 83 0.6× 34 0.3× 99 1.2k

Countries citing papers authored by Jie Jin

Since Specialization
Citations

This map shows the geographic impact of Jie Jin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jie Jin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jie Jin more than expected).

Fields of papers citing papers by Jie Jin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jie Jin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jie Jin. The network helps show where Jie Jin may publish in the future.

Co-authorship network of co-authors of Jie Jin

This figure shows the co-authorship network connecting the top 25 collaborators of Jie Jin. A scholar is included among the top collaborators of Jie Jin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jie Jin. Jie Jin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Yin, Xuejiao, Yi Liu, Jianping Ge, et al.. (2025). IFN-γ promotes the progression of iMCD by activating inflammatory monocytes. Blood. 146(1). 76–88.
3.
4.
Xie, Yan, Keshu Zhou, Lanfang Li, et al.. (2025). Phase 2 study of relmacabtagene autoleucel (CD19 CAR-T) for relapsed/refractory mantle cell lymphoma in Chinese adults. Blood Advances. 10(4). 1134–1144.
5.
6.
Shi, Yuanfei, Yi Xu, Huafei Shen, et al.. (2024). Advances in biology, diagnosis and treatment of DLBCL. Annals of Hematology. 103(9). 3315–3334. 14 indexed citations
7.
8.
9.
Sun, Mingyuan, Junyuan Qi, Lugui Qiu, et al.. (2023). A Phase 1 First-in-Human Monotherapy Study of F182112, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients with Relapsed or Refractory Multiple Myeloma. Blood. 142(Supplement 1). 1978–1978. 4 indexed citations
10.
Song, Yuqin, Dok Hyun Yoon, Haiyan Yang, et al.. (2023). Phase I dose escalation and expansion study of golidocitinib, a highly selective JAK1 inhibitor, in relapsed or refractory peripheral T-cell lymphomas. Annals of Oncology. 34(11). 1055–1063. 8 indexed citations
11.
Li, Fenglin, et al.. (2023). G Protein-Coupled Receptor 183 Plays a Prognostic Factor in Acute Myeloid Leukemia By Regulating Immune Regulation. Blood. 142(Supplement 1). 6043–6043. 1 indexed citations
12.
Wang, Yan, et al.. (2023). Chimeric antigen receptor natural killer cells: a promising antitumor immunotherapy. SHILAP Revista de lepidopterología. 4(6). e422–e422. 4 indexed citations
13.
Jin, Jie, et al.. (2022). The breather and semi-rational rogue wave solutions for the coupled mixed derivative nonlinear Schrödinger equations. Nonlinear Dynamics. 111(1). 633–643. 3 indexed citations
14.
An, Gang, Daobin Zhou, Shu Cheng, et al.. (2021). A Phase II Trial of the Bruton Tyrosine-Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Relapsed/Refractory Waldenström Macroglobulinemia. Clinical Cancer Research. 27(20). 5492–5501. 25 indexed citations
15.
Du, Juan, Baijun Fang, Li J, et al.. (2021). A study of carfilzomib and dexamethasone in patients with relapsed and refractory multiple myeloma in China. International Journal of Hematology. 113(3). 422–429. 5 indexed citations
16.
Lu, Jin, Weijun Fu, Wei Li, et al.. (2021). Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Chinese Patients with Relapsed or Refractory Multiple Myeloma: Phase 3 LEPUS (MMY3009) Study. Clinical Lymphoma Myeloma & Leukemia. 21(9). e699–e709. 23 indexed citations
17.
Song, Yuqin, Jianqiu Wu, Xinchuan Chen, et al.. (2019). A Single-Arm, Multicenter, Phase II Study of Camrelizumab in Relapsed or Refractory Classical Hodgkin Lymphoma. Clinical Cancer Research. 25(24). 7363–7369. 109 indexed citations
18.
19.
Chen, Jian, et al.. (2014). Vitamin D status and risk of non-Hodgkin lymphoma: a meta-analysis. Cancer Causes & Control. 25(11). 1553–1563. 17 indexed citations
20.
Shao, Genbao, Liuping Zhang, Pan Huang, et al.. (2014). Dynamic patterns of histone H3 lysine 4 methyltransferases and demethylases during mouse preimplantation development. In Vitro Cellular & Developmental Biology - Animal. 50(7). 603–613. 37 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Tarek H. Mouhieddine Breakdown of academic impact, for papers by Mary Kwok Breakdown of academic impact, for papers by Hussein A. Abbas Breakdown of academic impact, for papers by Agata Filip Breakdown of academic impact, for papers by Sara Redaelli Breakdown of academic impact, for papers by Christina Schmidt Breakdown of academic impact, for papers by Frances Bennett Breakdown of academic impact, for papers by Toby N. Trahair Breakdown of academic impact, for papers by R Schlossman Breakdown of academic impact, for papers by Cristina Ferrari
Rankless by CCL
2026